Allergic Asthma due to Dermatophagoides Farinae Market Summary

Allergic Asthma Due to Dermatophagoides Farinae Overview

Allergic asthma due to Dermatophagoides farinae (house dust mite) is a common form of IgE-mediated asthma triggered by inhalation of mite allergens found in household dust, bedding, and upholstered furniture. Exposure leads to airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction. It is often associated with other atopic conditions such as allergic rhinitis and atopic dermatitis.

Allergic Asthma Due to Dermatophagoides Farinae Diagnosis

Diagnosis is based on clinical history, lung function testing, and confirmation of allergen sensitization. Spirometry demonstrates reversible airflow limitation, while peak expiratory flow monitoring may help assess variability. Allergen sensitization is confirmed using skin prick testing or serum-specific IgE testing for Dermatophagoides farinae. In selected cases, bronchial provocation tests may be performed to assess airway responsiveness.

Allergic Asthma Due to Dermatophagoides Farinae Treatment

Management focuses on allergen avoidance, pharmacotherapy, and immunotherapy. Environmental control measures include dust mite–proof bedding covers, regular washing of linens in hot water, and reducing indoor humidity. Pharmacological treatment involves inhaled corticosteroids as controller therapy, bronchodilators for symptom relief, and leukotriene receptor antagonists in selected patients. Allergen-specific immunotherapy (subcutaneous or sublingual) may be considered for patients with persistent symptoms despite optimal medical management, as it can modify disease progression and reduce symptom severity.